Ahmed Nader is an Executive Director in Clinical Pharmacology and Quantitative Medicine (CPQM) at GSK, where he leads CPQM support for HBV and cardiovascular and metabolic comorbidities. Since joining GSK five years ago, he has led clinical pharmacology and quantitative medicine teams across high-priority development programs, with a focus on integrating model-informed drug development, quantitative systems pharmacology, and data-driven decision making.

Ahmed holds a PhD and MSc in Clinical Pharmacology from Purdue University and previously spent seven years at AbbVie supporting programs in Immunology and Specialty Medicine. His work is centered on applying quantitative clinical pharmacology to accelerate development, strengthen evidence generation, and inform strategic portfolio decisions.